Cargando…
Golimumab for the treatment of ulcerative colitis
Introduction: Tumor necrosis factor antagonists have revolutionized the therapeutic management of inflammatory bowel disease. Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis. More recently, a third tumor necrosis factor antagonis...
Autores principales: | Flamant, Mathurin, Paul, Stephane, Roblin, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490638/ https://www.ncbi.nlm.nih.gov/pubmed/28472597 http://dx.doi.org/10.1080/14712598.2017.1327576 |
Ejemplares similares
-
Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022) -
Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014) -
Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019) -
Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014) -
Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy
por: Chico, R Matthew, et al.
Publicado: (2011)